Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:PCVX NASDAQ:PHVS NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$32.78+5.2%$28.20$14.32▼$36.28$6.72B0.761.65 million shs763,716 shsPCVXVaxcyte$48.93+4.3%$55.49$29.08▼$65.00$7.08B1.241.41 million shs758,909 shsPHVSPharvaris$31.67+5.1%$29.01$15.91▼$33.33$2.07B-2.35233,599 shs269,094 shsQGENQiagen$37.78+3.6%$37.45$32.53▼$57.81$7.79B0.662.32 million shs2.24 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+0.74%-6.76%+14.86%+16.58%+101.75%PCVXVaxcyte-1.01%-8.02%-17.57%-19.43%+35.44%PHVSPharvaris+4.00%+2.27%+2.38%+16.64%+74.42%QGENQiagen+2.04%+0.82%+6.46%-21.45%-23.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$32.78+5.2%$28.20$14.32▼$36.28$6.72B0.761.65 million shs763,716 shsPCVXVaxcyte$48.93+4.3%$55.49$29.08▼$65.00$7.08B1.241.41 million shs758,909 shsPHVSPharvaris$31.67+5.1%$29.01$15.91▼$33.33$2.07B-2.35233,599 shs269,094 shsQGENQiagen$37.78+3.6%$37.45$32.53▼$57.81$7.79B0.662.32 million shs2.24 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+0.74%-6.76%+14.86%+16.58%+101.75%PCVXVaxcyte-1.01%-8.02%-17.57%-19.43%+35.44%PHVSPharvaris+4.00%+2.27%+2.38%+16.64%+74.42%QGENQiagen+2.04%+0.82%+6.46%-21.45%-23.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.3313.89% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0075.76% UpsidePHVSPharvaris 2.69Moderate Buy$49.1855.32% UpsideQGENQiagen 2.42Hold$44.9819.05% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, QGEN, PCVX, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/18/2026QGENQiagen Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$50.00 ➝ $36.005/18/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/13/2026PHVSPharvaris UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.005/13/2026PHVSPharvaris Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$75.00 ➝ $74.005/12/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/APCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/APHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/AQGENQiagen$2.09B3.73$3.60 per share10.48$17.89 per share2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)PHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%8/11/2026 (Estimated)QGENQiagen$424.88M$1.9119.7314.313.5519.16%14.40%8.40%8/4/2026 (Estimated)Latest PHVS, QGEN, PCVX, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/AQGENQiagen$0.260.69%N/A13.61%N/ALatest PHVS, QGEN, PCVX, and IMVT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09PCVXVaxcyteN/A7.497.49PHVSPharvarisN/A11.2411.24QGENQiagen0.493.212.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%PCVXVaxcyte96.78%PHVSPharvarisN/AQGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%PCVXVaxcyte3.30%PHVSPharvaris11.84%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionablePHVSPharvaris3065.41 million57.66 millionNot OptionableQGENQiagen5,654206.07 million187.53 millionOptionablePHVS, QGEN, PCVX, and IMVT HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENJune 4 at 10:00 AM | prnewswire.comQiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 3 at 4:03 PM | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENJune 2 at 5:41 PM | globenewswire.comEvaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price RecoveryJune 2 at 5:18 PM | finance.yahoo.comQiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate Conference - SlideshowJune 1 at 7:08 PM | seekingalpha.comLegal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGENMay 30, 2026 | marketbeat.comIs QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?May 29, 2026 | zacks.comQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakMay 28, 2026 | businesswire.comQIAGEN Business Breakdown and Growth Drivers for 2026May 28, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 28, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 26, 2026 | globenewswire.comQiagen N.V. (NYSE:QGEN) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 24, 2026 | americanbankingnews.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 21, 2026 | prnewswire.comQIAGEN Stock Up on the Launch of AI-Powered Workflow Agent PlatformMay 21, 2026 | zacks.comQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsMay 20, 2026 | businesswire.com3 Stocks in Focus That Recently Declared Dividend Hikes Amid High InflationMay 20, 2026 | zacks.comQiagen (QGEN) Securities Fraud Investigation - Levi & KorsinskyMay 20, 2026 | prnewswire.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 19, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 19, 2026 | globenewswire.comQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIAMay 19, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, QGEN, PCVX, and IMVT Company DescriptionsImmunovant NASDAQ:IMVT$32.78 +1.63 (+5.23%) As of 03:44 PM Eastern This is a fair market value price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Vaxcyte NASDAQ:PCVX$48.93 +2.00 (+4.26%) As of 03:44 PM Eastern This is a fair market value price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Pharvaris NASDAQ:PHVS$31.66 +1.53 (+5.06%) As of 03:44 PM Eastern This is a fair market value price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Qiagen NYSE:QGEN$37.78 +1.33 (+3.65%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
